Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa
NCT ID: NCT01448187
Last Updated: 2016-07-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
361 participants
OBSERVATIONAL
2012-01-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
NCT01203917
Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients
NCT02025218
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
NCT00298688
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
NCT01530334
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
NCT00234442
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient included in a therapeutic trial (Huriet-Serusclat Act)
* Patient refusing to participate in the study
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thierry BOUILLET, Dr
Role: PRINCIPAL_INVESTIGATOR
Bobigny
Elisabeth BRAMBILLA, Pr
Role: PRINCIPAL_INVESTIGATOR
Grenoble
Jacques CADRANEL, Pr
Role: PRINCIPAL_INVESTIGATOR
Paris
Jean-Francois MORERE, Pr
Role: PRINCIPAL_INVESTIGATOR
Bobigny
Maurice PEROL, Dr
Role: PRINCIPAL_INVESTIGATOR
Lyon
Virginie RONDEAU, PhD
Role: PRINCIPAL_INVESTIGATOR
Bordeaux
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aulnay-sous-Bois, , France
Research Site
Bayonne, , France
Research Site
Bordeaux, , France
Research Site
Bron, , France
Research Site
Carcassonne, , France
Research Site
Chalon-sur-Saône, , France
Research Site
Cholet, , France
Research Site
Clamart, , France
Research Site
Colmar, , France
Research Site
Corbeil-Essonnes, , France
Research Site
Créteil, , France
Research Site
Épernay, , France
Research Site
La Source, , France
Research Site
Marseille, , France
Research Site
Mâcon, , France
Reseacrh Site
Metz, , France
Research Site
Mont-de-Marsan, , France
Research Site
Niort, , France
Research Site
Paris, , France
Research Site
Pierre-Bénite, , France
Research Site
Quimper, , France
Research Site
Reims, , France
Research Site
Rouen, , France
Research Site
Saint-Herblain, , France
Research Site
Saint-Nazaire, , France
Research Site
Saint-Omer, , France
Research Site
Strasbourg, , France
Research Site
Toulon, , France
Research Site
Vienne, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
NIS-OFR-IRE-2011\_1CSR\_Synopsis.pdf
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-OFR-IRE-2011/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.